866-997-4948(US-Canada Toll Free)

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Pharmaceutical

No. of Pages : 163 Pages

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline Review, H1 2017, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 4 and 1 respectively.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development
Celgene Corp
CTI BioPharma Corp
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Incyte Corp
Italfarmaco SpA
JW Pharmaceutical Corp
MedImmune LLC
MEI Pharma Inc
Merck & Co Inc
Nippon Shinyaku Co Ltd
Novartis AG
Pfizer Inc
Promedior Inc
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drug Profiles
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CWP-291 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glasdegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCL-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pomalidomide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pracinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRM-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sonidegib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vismodegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones
Featured News & Press Releases
Dec 10, 2015: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Celgene Corp, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by CTI BioPharma Corp, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Gilead Sciences Inc, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corp, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco SpA, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by JW Pharmaceutical Corp, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MedImmune LLC, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MEI Pharma Inc, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Merck & Co Inc, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Pfizer Inc, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Promedior Inc, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, H1 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *